- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00453297
Phase I Study to Evaluate the Safety and Efficacy of MF101 as Well as the Pharmacokinetics of Its Key Active Components
August 27, 2008 updated by: Bionovo
A Randomized, Double-Blind, Placebo-Controlled, Single Dose, Oral, Dose Escalation Phase 1 Study to Evaluate the Safety and Tolerance of MF 101 as Well as the Pharmacokinetics of Its Key Active Components in Healthy Post-Menopausal Women.
This Phase I trial in healthy, post-menopausal women is designed as a double-blind, placebo-controlled, randomized, ascending single-dose safety trial.
MF101 will be administered as a single oral dose to a total of 32 enrolled subjects between the ages of 40-65 years.
Eight subjects will be assigned to each of four cohorts.
Within each cohort, six subjects will be randomized to receive MF101 and two subjects will receive placebo.
MF101 doses will be incrementally escalated until the stopping criteria are reached.
If stopping criteria are reached before the fourth cohort receives dosing, the next cohort may receive a dose between the dose that was administered to the cohort exhibiting symptoms of MF101 toxicity and the next lower dose group.
Study Overview
Detailed Description
The primary goal of this study is to identify the highest safe oral dose of MF101 that is well tolerated in humans.
Secondary goals include: characterizing clinical symptoms of MF101 toxicity in healthy subjects and evaluating the dose-dependent pharmacokinetics of key MF101 active components after a single oral dose.
Study Type
Interventional
Enrollment (Anticipated)
32
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80012
- University of Colorado Health Sciences Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Post-menopausal females, in good health and between 40 and 65 years of age.
- Normal body mass index equal or greater than 18 but not greater than 36
- Postmenopausal as defined by 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 30 mlU/ml or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy, or hysterectomy with FSH levels > 30 mlU/ml.
- Ability to comprehend and a willingness to sign an informed consent form.
- Ability and willingness to understand and follow study procedures.
- Clinical laboratory evaluations within the reference range for the testing laboratory, unless regarded not clinically significant by the Principle Investigator.
- Must have had mammogram within the last 9 months.
- Negative urine test for selected drugs of abuse at screening and after check-in at the study unit.
- Negative hepatitis panel (including HBsAg and anti-HCV), and HIV antibody screens.
- No chronic medications being taken.
- Must have a primary care physician.
Exclusion Criteria:
- History or clinical manifestations of significant metabolic, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, hepatic, gall bladder, renal, urological, or psychiatric disorders.
- Dyslipidemia
- History of abnormal renal function, uncontrolled hypertension, or malignancies.
- History of breast, uterine or ovarian cancer or melanoma.
- History of brain aneurism or ischemic events.
- Febrile disease
- Autoimmune disorders such as lupus erythematosis, multiple sclerosis or rheumatoid arthritis.
- Severe vasomotor symptoms defined as > 7/day or >50/week.
- Abnormal mammogram or breast examination within the last 9 months suggestive of cancer.
- Abnormal Pap smear or pelvic examination within the last 9 months suggestive of cancer.
- Double-wall endometrial thickness that exceeds 5 mm measured on transvaginal ultrasound.
- Unexplained abnormal uterine bleeding within six months of enrollment.
- Pregnancy or lactating.
- History of deep vein thrombosis or pulmonary embolism requiring anticoagulation.
- History of hypersensitivity or allergies to any drug compound, including the constituents of MF101 unless approved by the Principle Investigator.
- History or presence of a clinically significant abnormal ECG (QTcB > 450msec at screening or variation in QTcB > 30msec at screening).
- Likely to need medication during the study including contraceptives.
- History of alcoholism or drug addiction within 1 year prior to study entry (i.e., prior to check-in on Day-1).
- Use of any tobacco products (including cigarette, pipe, cigar, chewing, nicotine patch, or nicotine gum) within 6 months prior to study entry.
- Receipt of any investigational drug within 60 days prior to study entry.
- Use of prescription medications known to possibly be effective for the treatment of hot flashes within three months of enrollment for oral or transdermal drugs, or within 6 months of enrollment for implanted or injected drugs.
- Use of raloxifene, tamoxifen or aromatase inhibitors within three months of enrollment.
- Use of any other prescription medication or any alcohol-containing products/medications within 14 days prior to study entry.
- Use of over-the-counter, non-prescription preparations, within 7 days prior to study entry.
- Use of any caffeine-containing products/medications within 72 hours prior to study entry.
- Donation of blood within 6 weeks prior to study entry or of plasma within 2 weeks prior to screening.
- Receipt of blood products within 2 months prior to study entry.
- Any other condition or prior therapy which, in the opinion of the Investigator, would make the subject unsuitable for this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Identify the highest oral dose of MF101 that is safe and tolerated in humans.
|
Number and type of adverse events
|
Clinical laboratory including: Chemistry, hematology, blood coagulation and urinalysis
|
Physical exam and vital signs
|
Secondary Outcome Measures
Outcome Measure |
---|
Characterize MF101 toxicity and associated clinical symptoms in healthy subjects.
|
Establish cardiac safety (QTcB).
|
Study the dose dependent pharmacokinetics of MF101's key active components after oral administration.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Thomas Henthorn, University of Colorado, Denver
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2006
Study Completion (Actual)
April 1, 2007
Study Registration Dates
First Submitted
March 26, 2007
First Submitted That Met QC Criteria
March 27, 2007
First Posted (Estimate)
March 28, 2007
Study Record Updates
Last Update Posted (Estimate)
August 29, 2008
Last Update Submitted That Met QC Criteria
August 27, 2008
Last Verified
August 1, 2008
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- MF-101-003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on MF101
-
BionovoCompleted
-
BionovoUnknown
-
BionovoUnknown